ArticleWorld journal of surgical oncology2026
Serum 25(OH)D and HDL-C as site-specific metabolic markers of cervical lymph node metastasis in papillary thyroid carcinoma.
Article in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPreoperative risk stratification for cervical lymph node metastasis (LNM) is challenging in papillary thyroid carcinoma (PTC), metabolic disturbances may contribute to tumor progression and metastasis. This large retrospective cohort study investigated clinical and metabolic profiles to identify independent metabolic correlates associated with cervical LNM, which may complement preoperative risk assessment.
methodsA retrospective cohort analysis of 1,003 PTC patients was performed. Preoperative variables (demographics, clinicopathological features, serum biochemical markers) were profiled; univariate and multivariable logistic regression analyses were utilized to identify independent metabolic factors associated with central (CLNM) and lateral LNM (LLNM).
resultsAmong 1,003 patients, 35.19% and 3.79% presented with CLNM and LLNM, respectively. The LLNM subgroup was small (n = 38), which limited statistical power and generalizability of the corresponding findings. Multivariable analysis identified HDL-C (OR = 0.63, P = 0.040) as a factor independently associated with CLNM, and 25(OH)D (OR = 0.97, P = 0.012) with LLNM. Patients with 25(OH)D deficiency (< 50 nmol/L) had a higher LLNM incidence than those with sufficient levels (5.07% vs. 1.95%, P < 0.05). Tumor size remained a robust risk factor for both compartments, whereas BRAF V600E mutation showed no significant independent association with metastasis in this dataset (P > 0.05).
conclusionOur findings suggest that preoperative serum 25(OH)D and HDL-C are associated with site-specific LNM in PTC. These markers may complement preoperative risk stratification, although current evidence remains inconsistent. Given the retrospective, single-center design and small subgroup sizes, our results are preliminary and hypothesis-generating. Further prospective studies are needed to validate their clinical role.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.